January 17th 2025
Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.
January 14th 2025
Your daily dose of the clinical news you may have missed.
January 3rd 2025
The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.
December 19th 2024
A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data
January Issue of Patient Care Online Digital Edition is Now Live
Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.
Preventing Colon Cancer Before It Starts: Researchers Explore Novel Therapeutic Strategies
William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.
Counseling Patients on False Positives in cfDNA Blood-Based Colorectal Cancer Screening
William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.
Colorectal Cancer Screening: Considerations for Using Cell-Free DNA Blood Tests in Older Adults
William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.
Colorectal Cancer: How a New Blood-Based DNA Test Stacks Up in Screening Options
William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.
Advantages of Blood-Based Colorectal Cancer Screening: An Expert Discussion
William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.
Sharp Rise in Early-Onset Colorectal Cancer Mortality Among Young US Adults: Daily Dose
ECLIPSE Trial of Cell-Free DNA Blood-Based CRC Screening Test: Expert Overview
William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.
GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose
Patient Perspectives on Colonoscopies: Daily Dose
FIT Completion Rates Back Screening for CRC at Age 45: Daily Dose
Greatest Increase in Mortality from Early-Onset Colorectal Cancer Seen Among Youngest US Adults
ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.
GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D
ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.
Survey Reveals Patient Concerns Over Colonoscopy Prep, Barriers to Procedure
More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.
Similar Rates of FIT Completion Support Initiating CRC Screening at Age 45: New Research
Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.
Boost in CRC Screening after USPSTF Recommendation: Daily Dose
FDA Approves Next-Gen Noninvasive CRC Screening Test: Daily Dose
US Colorectal Cancer Screening Increased Three-Fold among Adults Aged 45-49 Years, but Disparities Persist
Increases in CRC screening were higher in high socioeconomic status and metropolitan areas, according to a new large cohort study.
FDA Approves Cologuard Plus, Next-Gen Noninvasive Colorectal Cancer Screening Test
Cologuard Plus bests its previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.
12 Facts About Colorectal Cancer for Primary Care Clinicians and Patients
Having a PCP is linked to higher rates of screening colonoscopy and improved overall survival. Review these 12 facts about CRC and share them with your patients.
Regular Aspirin Use for CRC Prevention Found to Benefit Unhealthy Adults Most: Daily Dose
Aspirin Use for Colorectal Cancer Prevention May Benefit Unhealthy Individuals Most
Regular aspirin use was associated with a greater absolute reduction in CRC incidence among adults with unhealthier lifestyles, according to recent research.
Novel Blood Test for CRC Screening Receives FDA Approval: Daily Dose
FDA Approves First Blood Test for Primary Screening of Colorectal Cancer
The Shield blood test is approved for primary CRC screening in adults 45 years and older at average risk for the disease.
GLP-1RAs Reduce Risk of Some Obesity-Related Cancers in Patients with T2D: Daily Dose
GLP-1RAs Linked to Decreased Risk of Some Obesity-Related Cancers in Patients with T2D
GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.
Blood-Based Test May be Effective Option for Colorectal Cancer Screening in Average-Risk Adults
DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.
Colorectal Cancer Rates Significantly Rising among Younger Adults and Teens, According to New Research
DDW 24. Among patients aged 15 to 19 years, the incidence of CRC rose 333% over a 22-year period, researchers reported.
FDA Approves Novel Noninvasive Multitarget Stool RNA CRC Screening Test: Daily Dose
FDA Approves ColoSense, Novel Noninvasive Multitarget Stool RNA CRC Screening Test
In average-risk individuals, the at-home ColoSense test demonstrated 93% sensitivity for detecting CRC and 45% sensitivity for detecting advanced adenomas.